Press Releases

Feb 11, 2020 AIM ImmunoTech Files Three Provisional Patent Applications Surrounding Ampligen(R) for Use Against the SARS-like Wuhan 2019 Novel Coronavirus

Feb 05, 2020 AIM ImmunoTech Announces Completion of Third-Party Clinical Trial Using Ampligen in Combination with Other Therapies as Adjuvant Treatment of Peritoneal Surface Malignancies

Dec 11, 2019 AIM ImmunoTech to Present at the Investor Summit in Philadelphia

Dec 04, 2019 AIM ImmunoTech Issues Stockholder Update and Details Its Expectations for 2020

Nov 15, 2019 CORRECTION: AIM ImmunoTech Provides Business Update for the Third Quarter of 2019

Nov 15, 2019 AIM ImmunoTech Provides Business Update for the Third Quarter of 2019

Oct 23, 2019 AIM ImmunoTech to Present at the Dawson James Securities 5th Annual Small Cap Growth Conference

Oct 07, 2019 AIM ImmunoTech Provides Comprehensive Clinical Trials Update With Major Inflection Points Identified

Sep 25, 2019 AIM ImmunoTech, Inc. Announces Pricing of $8 Million Public Offering

Sep 24, 2019 AIM ImmunoTech Inc. Announces a Second DoD Award, This One of $8.3 Million, to Fund Phase 2 Clinical Trial to Study Ampligen as Part of a New Treatment for Brain-Metastatic Breast Cancer at the Moffitt Cancer Center

5 6 7 8 9 10 11 12 13 14 15

<< < > >>